Stemline Therapeutics to Present Live Webcast on Monday, May 18, at UBS Global Healthcare Conference; Topics Include Novel Therapeutics for Wide Range of Blood Cancers and Systemic Mastocytosis

Stemline Therapeutics, Inc. (Nasdaq:STML), announced today that Ivan Bergstein, M.D., Stemline's CEO, will present at the UBS Global Healthcare Conference on Monday, May 18, 2015 at 2:30 PM ET. The conference will be held at the Sheraton New York Times Square in New York, NY. A live webcast of the presentation can be viewed on the company's website at Stemline Therapeutics, Inc., is a clinical stage biopharmaceutical company developing novel therapeutics that target cancer stem cells (CSCs) and tumor bulk. Stemline is developing two clinical stage product candidates, SL-401 and SL-701, and a pipeline of pre-clinical candidates that includes SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) present on CSCs and tumor bulk of a wide range of hematologic cancers. Three multicenter clinical trials with SL-401 are currently open in seven indications. SL-401 is currently completing the lead-in stage of the pivotal trial in blastic plasmacytoid dendritic cell neoplasm (BPDCN). Clinical studies with SL-401 are also open in additional hematologic indications including acute myeloid leukemia (AML) in first complete remission (CR) with minimal residual disease (MRD), relapsed/refractory AML, and four types of advanced high-risk myeloproliferative neoplasms (MPN), including systemic mastocytosis, advanced symptomatic hypereosinophilic disorder, myelofibrosis, and chronic myelomonocytic leukemia. SL-701, an immunotherapy designed to activate the immune system to attack tumors, is being developed in adult patients with glioblastoma multiforme (GBM) in first recurrence. SL-801, a novel oral small molecule reversible inhibitor of XPO1, is currently being advanced toward investigational new drug (IND) filing for clinical development in solid and hematologic cancers.
Login Or Register To Read Full Story